CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 241-252 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2024CrossrefDirectly related0 citations

Bibliometric analysis of chimeric antigen receptor T-cell therapy

2024CrossrefDirectly related0 citations

Application and progress of CAR therapy on malignances: from CAR-T to CAR-NK

Qi Zhang

Apr 16, 2024MedScien

2024CrossrefDirectly related219 citations

Development of NK cell-based cancer immunotherapies through receptor engineering

Audrey Page; Nicolas Chuvin; Jenny Valladeau-Guilemond; Stéphane Depil

Mar 5, 2024Cellular & Molecular Immunology

2024CrossrefDirectly related11 citations

Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma—Recent Advances

Adrian Kowalczyk; Julia Zarychta; Anna Marszołek; Joanna Zawitkowska; Monika Lejman

Jan 31, 2024Cancers

2023CrossrefDirectly related0 citations

Chimeric Antigen Receptor-T Cell Therapy with Breast Cancer

Tianyue Zhang

Dec 29, 2023Highlights in Science, Engineering and Technology

2023CrossrefDirectly related0 citations

CAR-T Cell Therapy: Revolutionizing Cancer Treatment with Engineered Immune Cells

Jiakai Fan

Dec 29, 2023Highlights in Science, Engineering and Technology

2023CrossrefDirectly related2 citations

Lentiviral Vectors in CAR-T Cell Manufacturing: Biological Principles, Manufacturing Process, and Frontier Development

Ge Yang

Dec 29, 2023Highlights in Science, Engineering and Technology

2023OpenAlexDirectly related15 citations

Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

Diego F. Chamorro; Lauren K. Somes; Valentina Hoyos

Dec 26, 2023Cancers

2023OpenAlexDirectly related24 citations

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Tingting Zhang; Weiwei Tian; Shuang Wei; Xinyi Lu; Jing An; Shaolong He; Jie Zhao; Zhilin Gao; Li Li; Ke Lian; Qiang Zhou; Huilai Zhang; Liang Wang; Liping Su; Huicong Kang; Ting Niu; Ailin Zhao; Jing Pan; Qingqing Cai; Zhenshu Xu; Wen-Ming Chen; Hongmei Jing; Peng Li; Wanhong Zhao; Yang Cao; Jian‐Qing Mi; Tao Chen; Yuan Chen; Ping Zou; Veronika Lukacs‐Kornek; Christian Kurts; Li J; Xiansheng Liu; Qi Mei; Yicheng Zhang; Wei Jia

Jul 27, 2023Experimental Hematology and Oncology

2023OpenAlexSupporting evidence17 citations

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy

Theo Lorenzini; Bruno L. Cadilha; Hannah Obeck; Mohamed-Reda Benmebarek; Florian Märkl; Stefanos Michaelides; Thaddäus Strzalkowski; Daria Briukhovetska; Philipp Jie Müller; Sayantan Nandi; Pia Winter; Lina Majed; Ruth Grünmeier; Matthias Seifert; Svenja Rausch; Tobias Feuchtinger; Stefan Endres; Sebastian Kobold

Jul 4, 2023British Journal of Cancer

2023CrossrefDirectly related7 citations

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations

Qi Zhang; Xiaojian Zhu; Bo Liu; Yicheng Zhang; Yi Xiao

Mar 17, 2023Frontiers in Immunology

2023OpenAlexDirectly related439 citations

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Estelle Baulu; Célia Gardet; Nicolas Chuvin; Stéphane Depil

Feb 15, 2023Science Advances